Company news
Jaguar Health, Inc. (MUN:1JA0) news
Jaguar Health, Inc. news releases on 6ix. Latest, Apr 7, 2026: Jaguar Health Reports 2025 Financials
Press releases & updates
Jaguar Health Reports 2025 Financials
April 7, 2026
Jaguar Health Announces a Special One-time Stock Dividend
February 18, 2026
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 24, 2025
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
September 30, 2025
Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
September 25, 2025
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
September 24, 2025
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
September 23, 2025
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
September 5, 2025
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
August 14, 2025
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca
July 8, 2025
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
June 26, 2025
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
June 25, 2025
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
June 24, 2025
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 21, 2025
Jaguar Health Reports First Quarter 2025 Financials
May 15, 2025